Compare TVRD & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TVRD | SABA |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.5M | 240.1M |
| IPO Year | N/A | N/A |
| Metric | TVRD | SABA |
|---|---|---|
| Price | $4.41 | $8.66 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $51.67 | N/A |
| AVG Volume (30 Days) | 114.5K | ★ 290.0K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.74 | $3.64 |
| 52 Week High | $43.65 | $4.42 |
| Indicator | TVRD | SABA |
|---|---|---|
| Relative Strength Index (RSI) | 34.35 | 43.30 |
| Support Level | $4.05 | $8.62 |
| Resistance Level | $4.71 | $8.79 |
| Average True Range (ATR) | 0.27 | 0.14 |
| MACD | 0.55 | -0.00 |
| Stochastic Oscillator | 73.20 | 14.29 |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.